Targeted delivery of puerarin/glycyrrhetinic acid-PEG-PBLA complex attenuated liver ischemia/reperfusion injury via modulating Toll-like receptor 4/nuclear factor-κB pathway
Author:
Affiliation:
1. Grade 2016, Clinical Medicine, Jiaxing University Medical College, Jiaxing 314001, ZJ, PR China
2. Department of Physiology & Diabetes Institute, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing University, Jiaxing 314001, ZJ, PR China
Abstract
Publisher
Future Science Ltd
Subject
Pharmaceutical Science
Link
http://www.future-science.com/doi/pdf/10.4155/tde-2017-0106
Reference47 articles.
1. Hepatic Ischemia/Reperfusion Injury Involves Functional TLR4 Signaling in Nonparenchymal Cells
2. In vitro and in vivo protein release and anti-ischemia/reperfusion injury properties of bone morphogenetic protein-2-loaded glycyrrhetinic acid-poly(ethylene glycol)-b-poly(L-lysine) nanoparticles
3. Hepatic ischemia/reperfusion injury—a fresh look
4. LIVER ISCHEMIA AND REPERFUSION INDUCES A SYSTEMIC INFLAMMATORY RESPONSE THROUGH KUPFFER CELL ACTIVATION
5. Apoptosis and necrosis in the liver: A tale of two deaths?
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Flavonoids-mediated TLR4 Inhibition as a Promising Therapy for Renal Diseases;Combinatorial Chemistry & High Throughput Screening;2023-10
2. Puerarin protects renal ischemia-reperfusion injury in rats through NLRP3/Caspase-1/GSDMD pathway;Acta Cirúrgica Brasileira;2023
3. Changes in the content of Puerarin-PLGA nanoparticles in mice under the influence of alcohol and analysis of their antialcoholism;Journal of Applied Biomaterials & Functional Materials;2023-01
4. Engineered nanoparticles as emerging gene/drug delivery systems targeting the nuclear factor-κB protein and related signaling pathways in cancer;Biomedicine & Pharmacotherapy;2022-12
5. Analysis of the network pharmacology and the structure-activity relationship of glycyrrhizic acid and glycyrrhetinic acid;Frontiers in Pharmacology;2022-10-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3